A randomized, double-blind, parallel-design, placebo-controlled study to evaluate the effects of 5 mg tadalafil (IC351, LY450190) and 50 mg sildenafil administered once daily for 6 months on visual function in healthy subjects or subjects with mild erectile dysfunction

Trial Profile

A randomized, double-blind, parallel-design, placebo-controlled study to evaluate the effects of 5 mg tadalafil (IC351, LY450190) and 50 mg sildenafil administered once daily for 6 months on visual function in healthy subjects or subjects with mild erectile dysfunction

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2007

At a glance

  • Drugs Sildenafil; Tadalafil
  • Indications Erectile dysfunction
  • Focus Pharmacodynamics
  • Sponsors Lilly ICOS
  • Most Recent Events

    • 09 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top